Sept. 15 - Amgen is set to present this week 25 reports on denosumab, a drug candidate that showed promise in cutting the risk of spinal, hip and other fractures in osteoporosis patients. The biotech firm is banking on denosumab to boost its shares and to make a strong impact on the $7 billion worldwide market for osteoporosis. Wall Street Journal